{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:14:48Z","timestamp":1791832488052,"version":"4.3.4"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40121-024-01063-5","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T15:01:49Z","timestamp":1730991709000},"page":"2489-2507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Global Epidemiology of Meningococcal Disease-Causing Serogroups Before and After the COVID-19 Pandemic: A Narrative Review"],"prefix":"10.1007","volume":"13","author":[{"given":"Steven","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1063_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fped.2018.00321","volume":"6","author":"S Nadel","year":"2018","unstructured":"Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321.","journal-title":"Front Pediatr"},{"key":"1063_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1474-4422(23)00195-3","volume":"22","author":"GBD 2019 Meningitis Antimicrobial Resistance Collaborators","year":"2023","unstructured":"GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023;22:685\u2013711.","journal-title":"Lancet Neurol"},{"key":"1063_CR3","unstructured":"European Centre for Disease Prevention and Control. Invasive Meningococcal Disease: Annual Epidemiological Report for 2018. Available at: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER-Invasive-meningococcal-disease-2018.pdf. Accessed 29 Mar 2023."},{"key":"1063_CR4","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268823000328","volume":"151","author":"C Pardo de Santayana","year":"2023","unstructured":"Pardo de Santayana C, Tin Tin Htar M, Findlow J, Balmer P. Epidemiology of invasive meningococcal disease worldwide from 2010\u20132019: a literature review. Epidemiol Infect. 2023;151: e57.","journal-title":"Epidemiol Infect"},{"key":"1063_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","volume":"799","author":"NG Rouphael","year":"2012","unstructured":"Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Bio. 2012;799:1\u201320.","journal-title":"Methods Mol Bio"},{"key":"1063_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s40121-021-00499-3","volume":"10","author":"L Soumahoro","year":"2021","unstructured":"Soumahoro L, Abitbol V, Vicic N, Bekkat-Berkani R, Safadi MAP. Meningococcal disease outbreaks: a moving target and a case for routine preventative vaccination. Infect Dis Ther. 2021;10:1949\u201388.","journal-title":"Infect Dis Ther"},{"key":"1063_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3201\/eid1904.111799","volume":"19","author":"OB Harrison","year":"2013","unstructured":"Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19:566\u201373.","journal-title":"Emerg Infect Dis"},{"key":"1063_CR8","first-page":"6","volume":"1","author":"J Leimkugel","year":"2009","unstructured":"Leimkugel J, Racloz V, Jacintho da Silva L, Pluschke G. Global review of meningococcal disease. A shifting etiology. J Bacteriol Res. 2009;1:6\u201318.","journal-title":"J Bacteriol Res."},{"key":"1063_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/14760584.2024.2329618","volume":"23","author":"R Borrow","year":"2024","unstructured":"Borrow R, Findlow J. The important lessons lurking in the history of meningococcal epidemiology. Expert Rev Vaccines. 2024;23:445\u201362.","journal-title":"Expert Rev Vaccines"},{"key":"1063_CR10","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","volume":"31","author":"O Xie","year":"2013","unstructured":"Xie O, Pollard A, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine. 2013;31:2852\u201361.","journal-title":"Vaccine"},{"key":"1063_CR11","unstructured":"World Health Organization. Control of Epidemic Meningitis in Countries in the African Meningitis Belt, 2017. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/272296\/WER9314.pdf?sequence=1. Accessed 31 Jan 2024."},{"key":"1063_CR12","unstructured":"Serum Institute of India Pvt. Ltd. Multivalent Meningococcal Meningitis Vaccine From Serum Institute of India Achieves WHO Prequalification. Available at: https:\/\/www.seruminstitute.com\/press_release_sii_120723.php. Accessed 24 July 2023."},{"key":"1063_CR13","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/microorganisms8101521","volume":"8","author":"M Pizza","year":"2020","unstructured":"Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. Microorganisms. 2020;8:1521.","journal-title":"Microorganisms"},{"key":"1063_CR14","unstructured":"Pfizer Inc. FDA Approves Penbraya\u2122, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents. Available at: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda-approves-penbrayatm-first-and-only-vaccine-prevention. Accessed 1 Apr 2024."},{"key":"1063_CR15","doi-asserted-by":"publisher","first-page":"B10","DOI":"10.1016\/j.vaccine.2011.12.060","volume":"30","author":"C Vipond","year":"2012","unstructured":"Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30:B10\u20137.","journal-title":"Vaccine"},{"issue":"27","key":"1063_CR16","first-page":"2002075","volume":"2022","author":"C Nuttens","year":"2008","unstructured":"Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2008;2022(27):2002075.","journal-title":"Euro Surveill"},{"key":"1063_CR17","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/INF.0b013e3180cc2c25","volume":"26","author":"DM Granoff","year":"2007","unstructured":"Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J. 2007;26:716\u201322.","journal-title":"Pediatr Infect Dis J"},{"key":"1063_CR18","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.3390\/microorganisms8111675","volume":"8","author":"SA Clark","year":"2020","unstructured":"Clark SA, Borrow R. Herd protection against meningococcal disease through vaccination. Microorganisms. 2020;8:1675.","journal-title":"Microorganisms"},{"key":"1063_CR19","unstructured":"MenFive (meningococcal [A, C, Y, W, X] polysaccharide conjugate vaccine [freeze-dried]). Full Prescribing Information, Serum Institute of India, Hadapsar, India, 2023."},{"key":"1063_CR20","unstructured":"Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine). Summary of Product Characteristics, Pfizer Europe, Bruxelles, Belgium, 2023."},{"key":"1063_CR21","unstructured":"Menjugate Liquid (meningococcal group C conjugate vaccine, 10 micrograms suspension for injection). Summary of Product Characteristics, GlaxoSmithKline Inc., Mississauga, ON, Canada, 2020."},{"key":"1063_CR22","unstructured":"NeisVac-C (meningococcal group C-TT conjugate vaccine, adsorbed). Summary of Product Characteristics, Pfizer Canada ULC, Kirkland, QC, Canada, 2021."},{"key":"1063_CR23","unstructured":"Menveo (meningococcal [groups A, C, Y, and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine). Full Prescribing Information, GlaxoSmithKline, Durham, NC, 2022."},{"key":"1063_CR24","unstructured":"MenAfriVac (meningococcal A conjugate vaccine lyophilized). Full Prescribing Information, Serum Institute of India PVT. LTD., Pune, India, 2024."},{"key":"1063_CR25","unstructured":"GlaxoSmithKline. Menitorix (Haemophilus Type b and Meningococcal Group C Conjugate Vaccine) Package Leaflet. Available at: https:\/\/www.medicines.org.uk\/emc\/files\/pil.167.pdf. Accessed 26 Jan 2024."},{"key":"1063_CR26","unstructured":"MenQuadfi (meningococcal group A, C, W and Y conjugate vaccine). Summary of Product Characteristics, Sanofi Pasteur, Inc., Val de Reuil, France, 2020."},{"key":"1063_CR27","unstructured":"Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine). Full Prescribing Information, Sanofi Pasteur Inc., Swiftwater, PA, 2018."},{"key":"1063_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","volume":"21","author":"J Findlow","year":"2022","unstructured":"Findlow J, Lucidarme J, Taha MK, Burman C, Balmer P. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Rev Vaccines. 2022;21:739\u201351.","journal-title":"Expert Rev Vaccines"},{"key":"1063_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14760584.2022.2064850","volume":"21","author":"J Findlow","year":"2022","unstructured":"Findlow J, Borrow R, Stephens DS, et al. Correlates of protection for meningococcal surface protein vaccines: current approaches for the determination of breadth of coverage. Expert Rev Vaccines. 2022;21:753\u201369.","journal-title":"Expert Rev Vaccines"},{"key":"1063_CR30","unstructured":"Trumenba (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc, Philadelphia, PA, 2024."},{"key":"1063_CR31","unstructured":"Bexsero (meningococcal group B vaccine). Full Prescribing Information, GlaxoSmithKline, Durham, NC, 2023."},{"key":"1063_CR32","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1016\/j.vaccine.2018.05.081","volume":"36","author":"SL Harris","year":"2018","unstructured":"Harris SL, Tan C, Andrew L, et al. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci. Vaccine. 2018;36:6867\u201374.","journal-title":"Vaccine"},{"key":"1063_CR33","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1080\/21645515.2020.1855951","volume":"17","author":"C Fazio","year":"2021","unstructured":"Fazio C, Biolchi A, Neri A, et al. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy. Hum Vaccin Immunother. 2021;17:2225\u201331.","journal-title":"Hum Vaccin Immunother"},{"key":"1063_CR34","unstructured":"GlaxoSmithKline. Pipeline. Available at: https:\/\/www.gsk.com\/en-gb\/innovation\/pipeline\/?infectious-diseases. Accessed 28 Feb 2024."},{"key":"1063_CR35","unstructured":"ClinicalTrials.gov. Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04502693. Accessed 30 Aug 2024."},{"key":"1063_CR36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jinf.2022.09.001","volume":"85","author":"R Bekkat-Berkani","year":"2022","unstructured":"Bekkat-Berkani R, Fragapane E, Preiss S, et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85:481\u201391.","journal-title":"J Infect"},{"key":"1063_CR37","unstructured":"ClinicalTrials.gov. A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05082285. Accessed 28 Feb 2024."},{"key":"1063_CR38","unstructured":"ClinicalTrials.gov. Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06128733. Accessed 28 Feb 2024."},{"key":"1063_CR39","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1016\/j.vaccine.2016.10.022","volume":"34","author":"R Borrow","year":"2016","unstructured":"Borrow R, Lee JS, Vazquez JA, et al. Meningococcal disease in the Asia-Pacific region: findings and recommendations from the Global Meningococcal Initiative. Vaccine. 2016;34:5855\u201362.","journal-title":"Vaccine"},{"key":"1063_CR40","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/S1473-3099(17)30301-8","volume":"17","author":"CL Trotter","year":"2017","unstructured":"Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010\u201315: an analysis of surveillance data. Lancet Infect Dis. 2017;17:867\u201372.","journal-title":"Lancet Infect Dis"},{"key":"1063_CR41","unstructured":"World Health Organization. Control of Epidemic Meningitis in Countries in the African Meningitis Belt, 2018. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/311706\/WER9414-15-179-188.pdf?sequence=1&isAllowed=y. Accessed 31 Jan 2024."},{"key":"1063_CR42","unstructured":"World Health Organization. Control of Epidemic Meningitis in Countries in the African Meningitis Belt, 2019. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/331663\/WER9514-15-133-143-eng-fre.pdf?sequence=1&isAllowed=y. Accessed 30 Jan 2024."},{"key":"1063_CR43","unstructured":"World Health Organization. Control of Epidemic Meningitis in Countries in the African Meningitis Belt, 2020. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/344060\/WER9632-365-375-eng-fre.pdf?sequence=1&isAllowed=y. Accessed 30 Jan 2024."},{"key":"1063_CR44","unstructured":"World Health Organization. Control of Epidemic Meningitis in Countries in the African Meningitis Belt, 2021. Available at: https:\/\/iris.who.int\/bitstream\/handle\/10665\/362153\/WER9735-409-423-eng-fre.pdf?sequence=1&isAllowed=y. Accessed 30 Jan 2024."},{"key":"1063_CR45","first-page":"457","volume":"39","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Control of epidemic meningitis in countries in the African meningitis belt, 2022. Wkly Epidemiol Rec. 2023;39:457\u201370.","journal-title":"Wkly Epidemiol Rec"},{"key":"1063_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jinf.2023.09.002","volume":"87","author":"SA Clark","year":"2023","unstructured":"Clark SA, Campbell H, Ribeiro S, et al. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England. J Infect. 2023;87:385\u201391.","journal-title":"J Infect"},{"key":"1063_CR47","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jiph.2023.10.001","volume":"16","author":"S Taha","year":"2023","unstructured":"Taha S, Hong E, Denizon M, et al. The rapid rebound of invasive meningococcal disease in France at the end of 2022. J Infect Public Health. 2023;16:1954\u201360.","journal-title":"J Infect Public Health"},{"key":"1063_CR48","unstructured":"Australian Government Department of Health and Aged Care. National Notifiable Diseases Surveillance System (NNDSS) Public Dataset \u2013 Meningococcal Disease (Invasive). Available at: https:\/\/www.health.gov.au\/resources\/publications\/national-notifiable-diseases-surveillance-system-nndss-public-dataset-meningococcal-disease-invasive. Accessed 25 Jan 2024."},{"key":"1063_CR49","unstructured":"Instituto de Salud P\u00fablica de Chile. Informe de Resultados de Vigilancia de Laboratorio Enfermedad Invasora Neisseria meningitidis 2020. Available at: https:\/\/www.ispch.gob.cl\/wp-content\/uploads\/2021\/02\/Informe-Neisseria-meningitidis-SE-1-53-2020-v1-1.pdf. Accessed 29 Feb 2024."},{"key":"1063_CR50","unstructured":"Institute of Public Health of Chile. Laboratory Surveillance Results Report Invasive Disease Neisseria meningitidis. Chile, 2022. Available at: https:\/\/www.ispch.cl\/wp-content\/uploads\/2023\/03\/Informe-Neisseria-meningitidis-SE-1-52-2022.pdf. Accessed 29 Feb 2024."},{"key":"1063_CR51","unstructured":"Instituto de Salud P\u00fablica de Chile. Informe de Resultados de Vigilancia de Laboratorio Enfermedad Invasora Neisseria meningitidis. Chile, SE N\u00b01\u201339 2023. Available at: https:\/\/www.ispch.gob.cl\/wp-content\/uploads\/2023\/11\/Informe-N.-meningitidis-final_SE-1-39_16nov2023v4.pdf. Accessed 29 Feb 2024."},{"key":"1063_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2019.103571","volume":"134","author":"A Purmohamad","year":"2019","unstructured":"Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Pathog. 2019;134: 103571.","journal-title":"Microb Pathog"},{"key":"1063_CR53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamapediatrics.2020.1990","volume":"174","author":"S Mbaeyi","year":"2020","unstructured":"Mbaeyi S, Pondo T, Blain A, et al. Incidence of meningococcal disease before and after implementation of quadrivalent meningococcal conjugate vaccine in the United States. JAMA Pediatr. 2020;174:843\u201351.","journal-title":"JAMA Pediatr"},{"key":"1063_CR54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81:483\u201398.","journal-title":"J Infect"},{"key":"1063_CR55","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s40121-023-00888-w","volume":"12","author":"DE Bloom","year":"2023","unstructured":"Bloom DE, Bonanni P, Martinon-Torres F, et al. Meningococcal disease in the post-COVID-19 era: a time to prepare. Infect Dis Ther. 2023;12:2649\u201363.","journal-title":"Infect Dis Ther"},{"key":"1063_CR56","unstructured":"UK National Health Service. Vaccination: Meningitis. Available at: https:\/\/www.nhs.uk\/conditions\/meningitis\/vaccination\/. Accessed 24 Jan 2024."},{"key":"1063_CR57","unstructured":"Health Protection Surveillance Centre (Ireland). Bacterial Meningitis\/Septicaemia in Ireland. Available at: https:\/\/www.hpsc.ie\/a-z\/vaccinepreventable\/bacterialmeningitis\/news\/title-22705-en.html. Accessed 29 Jan 2024."},{"key":"1063_CR58","unstructured":"Health Protection Surveillance Centre (Ireland). Infectious Disease Notifications in Ireland, 2018 - 2022. Available at: https:\/\/www.hpsc.ie\/notifiablediseases\/annualidstatistics\/Annual_ID_Summary_Report_for_HPSC_Web_v8.0-2018-2022-21032023.pdf. Accessed 1 Apr 2024."},{"key":"1063_CR59","unstructured":"Health Protection Surveillance Centre (Ireland). Infectious Disease Notifications in Ireland, 2019 - 2023. Available at: https:\/\/www.hpsc.ie\/notifiablediseases\/annualidstatistics\/Annual_ID_Summary_Report_for_HPSC_Web_v9.0-2019-2023-03102024.pdf. Accessed 15 Oct 2024."},{"key":"1063_CR60","unstructured":"French Republic FA. Immunization Schedule. Available at: https:\/\/www.service-public.fr\/particuliers\/vosdroits\/F724. Accessed 12 Mar 2024."},{"key":"1063_CR61","unstructured":"National Center for Immunisation Research and Surveillance Australia. Annual Immunisation Coverage Report: 2022. Available at: https:\/\/ncirs.org.au\/sites\/default\/files\/2024-01\/NCIRS%20Annual%20immunisation%20coverage%20report%202022.pdf. Accessed 5 Mar 2024."},{"key":"1063_CR62","doi-asserted-by":"publisher","first-page":"2251825","DOI":"10.1080\/21645515.2023.2251825","volume":"19","author":"R Villena","year":"2023","unstructured":"Villena R, Kriz P, Tin Tin Htar M, et al. Real-world impact and effectiveness of MenACWY-TT. Hum Vaccin Immunother. 2023;19:2251825.","journal-title":"Hum Vaccin Immunother"},{"key":"1063_CR63","unstructured":"Australian Government Department of Health and Aged Care. National Immunisation Program Schedule. Available at: https:\/\/www.health.gov.au\/topics\/immunisation\/when-to-get-vaccinated\/national-immunisation-program-schedule. Accessed 25 Jan 2024."},{"key":"1063_CR64","unstructured":"Instituto de Salud P\u00fablica de Chile. Informe de Resultados de Vigilancia de Laboratorio Enfermedad Invasora Neisseria meningitidis 2021. Available at: https:\/\/www.ispch.gob.cl\/wp-content\/uploads\/2022\/06\/Informe-Neisseria-meningitidis-SE-1-52-2021-rv2-.pdf. Accessed 29 Feb 2024."},{"key":"1063_CR65","unstructured":"European Centre for Disease Prevention and Control. Vaccine Scheduler. Meningococcal Disease: Recommended Vaccinations. Available at: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1. Accessed 24 Jan 2024."},{"key":"1063_CR66","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","volume":"15","author":"V Vetter","year":"2016","unstructured":"Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission & disease. Expert Rev Vaccines. 2016;15:641\u201358.","journal-title":"Expert Rev Vaccines"},{"key":"1063_CR67","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","author":"SJ Gray","year":"2006","unstructured":"Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55:887\u201396.","journal-title":"J Med Microbiol"},{"key":"1063_CR68","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jinf.2015.07.007","volume":"71","author":"J Lucidarme","year":"2015","unstructured":"Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71:544\u201352.","journal-title":"J Infect"},{"key":"1063_CR69","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1186\/s12889-020-09946-1","volume":"20","author":"M Tin Tin Htar","year":"2020","unstructured":"Tin Tin Htar M, Jackson S, Balmer P, et al. Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs. BMC Public Health. 2020;20:1890.","journal-title":"BMC Public Health"},{"key":"1063_CR70","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/S0140-6736(20)30913-2","volume":"395","author":"SN Ladhani","year":"2020","unstructured":"Ladhani SN, Lucidarme J, Parikh SR, et al. Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis. Lancet. 2020;395:1865\u201377.","journal-title":"Lancet"},{"key":"1063_CR71","unstructured":"World Health Organization. Disease Outbreak News: Meningitis - Nigeria. Available at: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2023-DON454. Accessed 29 Jan 2024."},{"key":"1063_CR72","unstructured":"US Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Reports. Available at: https:\/\/stacks.cdc.gov\/view\/cdc\/140468. Accessed 30 Jan 2024."},{"key":"1063_CR73","unstructured":"US Centers for Disease Control and Prevention. Nationally Notifiable Infectious Diseases and Conditions, United States: Weekly Tables. Available at: https:\/\/wonder.cdc.gov\/nndss\/static\/2023\/52\/2023-52-table920-H.pdf. Accessed 30 Jan 2024."},{"key":"1063_CR74","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease: Surveillance and Trends. Available at: https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/meningococcal\/surveillance\/. Accessed March 14, 2024."},{"key":"1063_CR75","unstructured":"US Centers for Disease Control and Prevention. Meningococcal Disease Outbreak Among Gay, Bisexual Men in Florida, 2021\u201323. Available at: https:\/\/www.cdc.gov\/meningococcal\/outbreaks\/FL2022.html. Accessed 30 Jan 2024."},{"key":"1063_CR76","unstructured":"US Centers for Disease Control and Prevention. Nationally Notifiable Infectious Diseases and Conditions, United States: Weekly Tables. Available at: https:\/\/wonder.cdc.gov\/nndss\/static\/2022\/52\/2022-52-table1w-H.pdf. Accessed 30 Jan 2024."},{"key":"1063_CR77","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.vaccine.2016.02.014","volume":"34","author":"MM Mustapha","year":"2016","unstructured":"Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970\u20132015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34:1515\u201323.","journal-title":"Vaccine"},{"key":"1063_CR78","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/microorganisms9030519","volume":"9","author":"YL Tzeng","year":"2021","unstructured":"Tzeng YL, Stephens DS. A narrative review of the W, X, Y, E, and NG of meningococcal disease: emerging capsular groups, pathotypes, and global control. Microorganisms. 2021;9:519.","journal-title":"Microorganisms"},{"key":"1063_CR79","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1080\/21645515.2020.1855952","volume":"17","author":"L Serra","year":"2021","unstructured":"Serra L, Knuf M, Martinon-Torres F, Yi K, Findlow J. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines. Hum Vaccin Immunother. 2021;17:2205\u201315.","journal-title":"Hum Vaccin Immunother"},{"key":"1063_CR80","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41541-022-00488-8","volume":"7","author":"S Taha","year":"2022","unstructured":"Taha S, Taha MK, Deghmane AE. Impact of mandatory vaccination against serogroup C meningococci in targeted and non-targeted populations in France. NPJ Vaccines. 2022;7:73.","journal-title":"NPJ Vaccines"},{"key":"1063_CR81","unstructured":"Instituto de Salud P\u00fablica de Chile. Calendario de Vacunaci\u00f3n 2023. Available at: https:\/\/www.ispch.gob.cl\/wp-content\/uploads\/2023\/04\/CALENDARIO-VACUNACION-2023_final.pdf. Accessed 29 Feb 2024."},{"key":"1063_CR82","unstructured":"World Health Organization. Introduction of Meningococcal Meningitis Vaccines (All Strains). Available at: https:\/\/immunizationdata.who.int\/global\/wiise-detail-page\/introduction-of-meningococcal-meningitis-vaccines-(all-strains)?ISO_3_CODE=&YEAR. Accessed 4 Mar 2024."},{"key":"1063_CR83","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jinf.2021.11.016","volume":"84","author":"MR Alderson","year":"2022","unstructured":"Alderson MR, Arkwright PD, Bai X, et al. Surveillance and control of meningococcal disease in the COVID-19 era: a Global Meningococcal Initiative review. J Infect. 2022;84:289\u201396.","journal-title":"J Infect"},{"key":"1063_CR84","volume-title":"Invasive Meningococcal Disease. ECDC Annual Epidemiological Report for 2022. Vol 2024","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2022","unstructured":"European Centre for Disease Prevention and Control (ECDC). Invasive Meningococcal Disease. ECDC Annual Epidemiological Report for 2022. Vol 2024. Stockholm: European Centre for Disease Prevention and Control; 2022."},{"key":"1063_CR85","unstructured":"Virginia Department of Health. Virginia Department of Health Declares Statewide Outbreak of Meningococcal Disease. Available at: https:\/\/www.vdh.virginia.gov\/clinicians\/virginia-department-of-health-declares-statewide-outbreak-of-meningococcal-disease\/. Accessed 18 Jan 2024."},{"key":"1063_CR86","first-page":"48","volume":"2024","author":"MM Lahra","year":"2018","unstructured":"Lahra MM, Latham NH, Templeton DJ, et al. Investigation and response to an outbreak of Neisseria meningitidis serogroup Y ST-1466 urogenital infections. Australia Commun Dis Intell. 2018;2024:48.","journal-title":"Australia Commun Dis Intell"},{"key":"1063_CR87","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10123-023-00325-5","volume":"26","author":"AP Cassiolato","year":"2023","unstructured":"Cassiolato AP, Camargo CH, Piccoli Cecconi MC, et al. Genomic characterization of invasive meningococcal X isolates from Brazil, 1992\u20132022. Int Microbiol. 2023;26:611\u20138.","journal-title":"Int Microbiol"},{"key":"1063_CR88","doi-asserted-by":"publisher","first-page":"619","DOI":"10.4269\/ajtmh.2009.80.619","volume":"80","author":"DM Mutonga","year":"2009","unstructured":"Mutonga DM, Pimentel G, Muindi J, et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005\u20132006. Am J Trop Med Hyg. 2009;80:619\u201324.","journal-title":"Am J Trop Med Hyg"},{"key":"1063_CR89","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1046\/j.1469-0691.2003.00685.x","volume":"9","author":"CM del Castillo","year":"2003","unstructured":"del Castillo CM, Vazquez JA, Romero J, Pascual A. Infections by Neisseria meningitidis serogroup X in Spain. Clin Microbiol Infect. 2003;9:964\u20135.","journal-title":"Clin Microbiol Infect"},{"key":"1063_CR90","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1016\/j.vaccine.2023.06.078","volume":"41","author":"WR Miellet","year":"2023","unstructured":"Miellet WR, Pluister G, Sikking M, et al. Surveillance of Neisseria meningitidis carriage four years after menACWY vaccine implementation in the Netherlands reveals decline in vaccine-type and rise in genogroup E circulation. Vaccine. 2023;41:4927\u201332.","journal-title":"Vaccine"},{"key":"1063_CR91","doi-asserted-by":"publisher","first-page":"2000375","DOI":"10.2807\/1560-7917.ES.2020.25.15.2000375","volume":"25","author":"A Brooks","year":"2020","unstructured":"Brooks A, Lucidarme J, Campbell H, et al. Detection of the United States Neisseria meningitidis urethritis clade in the United Kingdom, August and December 2019 - emergence of multiple antibiotic resistance calls for vigilance. Euro Surveill. 2020;25:2000375.","journal-title":"Euro Surveill"},{"key":"1063_CR92","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","volume":"5","author":"D Shaw","year":"2023","unstructured":"Shaw D, Abad R, Amin-Chowdhury Z, et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health. 2023;5:e582\u201393.","journal-title":"Lancet Digit Health"},{"key":"1063_CR93","unstructured":"UNICEF. COVID-19 Pandemic Leads to Major Backsliding on Childhood Vaccinations, New WHO, UNICEF Data Shows. Available at: https:\/\/www.unicef.org\/press-releases\/covid-19-pandemic-leads-major-backsliding-childhood-vaccinations-new-who-unicef-data. Accessed 10 Jan 2022."},{"key":"1063_CR94","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1080\/21645515.2020.1804776","volume":"17","author":"EC Dinleyici","year":"2021","unstructured":"Dinleyici EC, Borrow R, Safadi MAP, van Damme P, Munoz FM. Vaccines and routine immunization strategies during the COVID-19 pandemic. Hum Vaccin Immunother. 2021;17:400\u20137.","journal-title":"Hum Vaccin Immunother"},{"key":"1063_CR95","unstructured":"GlaxoSmithKline. Half of parents surveyed either cancelled or delayed their child\u2019s scheduled meningitis vaccination during the COVID-19 pandemic \u2013 GSK survey shows. Available at: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/half-of-parents-surveyed-either-cancelled-or-delayed-their-child-s-scheduled-meningitis-vaccination-during-the-covid-19-pandemic-gsk-survey-shows-1\/. Accessed 17 May 2022."},{"key":"1063_CR96","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.idnow.2021.05.004","volume":"51","author":"R Cohen","year":"2021","unstructured":"Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51:418\u201323.","journal-title":"Infect Dis Now"},{"key":"1063_CR97","unstructured":"US Centers for Disease Control and Prevention. TeenVaxView: Vaccination Coverage Among Adolescents (13\u201317 Years). Available at: https:\/\/www.cdc.gov\/vaccines\/imz-managers\/coverage\/teenvaxview\/data-reports\/index.html. Accessed 5 Apr 2024."},{"key":"1063_CR98","unstructured":"World Health Organization. Disease Outbreak News: Meningitis - Democratic Republic of the Congo. Available at: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2021-DON334. Accessed 30 Jan 2024."},{"key":"1063_CR99","unstructured":"World Health Organization. Meningitis Outbreak in Democratic Republic of the Congo Declared Over. Available at: https:\/\/www.afro.who.int\/news\/meningitis-outbreak-democratic-republic-congo-declared-over. Accessed 30 Jan 2024."},{"key":"1063_CR100","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2206433","volume":"388","author":"J Castilla","year":"2023","unstructured":"Castilla J, Garcia Cenoz M, Abad R, et al. Effectiveness of a meningococcal group B vaccine (4CMenB) in children. N Engl J Med. 2023;388:427\u201338.","journal-title":"N Engl J Med"},{"key":"1063_CR101","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1093\/cid\/ciaa1636","volume":"73","author":"M McMillan","year":"2021","unstructured":"McMillan M, Wang B, Koehler AP, Sullivan TR, Marshall HS. Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents. Clin Infect Dis. 2021;73:e233\u20137.","journal-title":"Clin Infect Dis"},{"key":"1063_CR102","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29678","volume":"6","author":"L Lodi","year":"2023","unstructured":"Lodi L, Barbati F, Amicizia D, et al. Four-component recombinant protein-based vaccine effectiveness against serogroup B meningococcal disease in Italy. JAMA Netw Open. 2023;6: e2329678.","journal-title":"JAMA Netw Open"},{"key":"1063_CR103","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s40121-022-00609-9","volume":"11","author":"GS Marshall","year":"2022","unstructured":"Marshall GS, Fergie J, Presa J, Peyrani P. Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review. Infect Dis Ther. 2022;11:937\u201351.","journal-title":"Infect Dis Ther"},{"key":"1063_CR104","unstructured":"Bexsero (meningococcal group B vaccine [rDNA, component, adsorbed]). Summary of Product Characteristics, GSK Vaccines, Sovicille, Italy, 2024."},{"key":"1063_CR105","unstructured":"Trumenba (meningococcal group B vaccine). Summary of Product Characteristics, Pfizer Europe MA EEIG, Bruxelles, Belgium, 2022."},{"key":"1063_CR106","unstructured":"Sanofi. Innovation to Drive Sustainable Growth in Vaccines: Part 1. Available at: https:\/\/www.sanofi.com\/assets\/dotcom\/content-app\/events\/investor-presentation\/2023\/vaccines-investor-event\/presentation-vaccines-event-2023.pdf. Accessed 28 Feb 2024."},{"key":"1063_CR107","unstructured":"Penbraya (meningococcal groups A, B, C, W, and Y vaccine). Full Prescribing Information, Pfizer Ireland Pharmaceuticals, Cork, Ireland, 2023."},{"key":"1063_CR108","unstructured":"Sanofi. Vaccines Investor Event: Sanofi Reiterates Confidence in Strong Growth Outlook and Showcases Pipeline of Innovative Vaccine Candidates. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2021\/2021-12-01-06-30-00-2343730. Accessed 28 Feb 2024."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01063-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01063-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T15:09:50Z","timestamp":1732201790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01063-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":108,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1063"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01063-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Steven Shen, Jamie Findlow, and Paula Peyrani are employees of Pfizer and may hold stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}